Frederic A Houssiau
Overview
Explore the profile of Frederic A Houssiau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
2699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Houssiau F
Biol Aujourdhui
. 2024 Jul;
218(1-2):25-31.
PMID: 39007774
Lupus nephritis remains the most frequent severe complication of systemic lupus erythematosus, leading to chronic renal impairment in 20 to 25% of cases. Current treatment is based on the combined...
2.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S, et al.
Ann Rheum Dis
. 2023 Oct;
83(1):15-29.
PMID: 37827694
Objectives: To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods: An international Task Force formed the questions for the systematic...
3.
Parodis I, Lindblom J, Cetrez N, Palazzo L, Ala H, Houssiau F, et al.
Kidney Int Rep
. 2023 Sep;
8(9):1822-1830.
PMID: 37705915
Introduction: Belimumab was recently approved for treating lupus nephritis (LN), yet LN cases during belimumab treatment given for nonrenal causes have been reported. Identification of reliable signals of impending flare...
4.
Montigny P, Houssiau F
Arch Immunol Ther Exp (Warsz)
. 2022 Mar;
70(1):11.
PMID: 35298708
The aim of this study is to report major recent progresses in the treatment of lupus nephritis (LN). Results of controlled randomized trials are discussed in view of the unmet...
5.
Parodis I, Tamirou F, Houssiau F
Arch Immunol Ther Exp (Warsz)
. 2022 Feb;
70(1):8.
PMID: 35147824
Kidney involvement, termed lupus nephritis (LN), develops in 35-60% of patients with systemic lupus erythematosus, often early during the disease course. When not treated promptly and efficiently, LN may lead...
6.
Jayne D, Rovin B, Mysler E, Furie R, Houssiau F, Trasieva T, et al.
Ann Rheum Dis
. 2022 Feb;
81(4):496-506.
PMID: 35144924
Objective: To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods: This phase II double-blinded study...
7.
van Vollenhoven R, Bertsias G, Doria A, Isenberg D, Morand E, Petri M, et al.
Lupus Sci Med
. 2021 Nov;
8(1).
PMID: 34819388
Objective: To achieve consensus on a definition of remission in SLE (DORIS). Background: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission...
8.
Parodis I, Houssiau F
Ann Rheum Dis
. 2021 Sep;
81(1):15-19.
PMID: 34521616
The current treatment paradigm in lupus nephritis consists of an initial phase aimed at inducing remission and a subsequent remission maintenance phase. With this so-called sequential treatment approach, complete renal...
9.
Pirson V, Enfrein A, Houssiau F, Tamirou F
Lupus Sci Med
. 2021 Aug;
8(1).
PMID: 34446568
Background: The very long-term consequences of absence of remission in lupus nephritis (LN) remain understudied. Methods: In this retrospective analysis, we studied a selected cohort of 128 patients with biopsy-proven...
10.
Chavatza K, Kostopoulou M, Nikolopoulos D, Gioti O, Togia K, Andreoli L, et al.
Ann Rheum Dis
. 2021 Jun;
80(9):1175-1182.
PMID: 34162597
Background: Quality of care is receiving increased attention in systemic lupus erythematosus (SLE). We developed quality indicators (QIs) for SLE based on the 2019 update of European League Against Rheumatism...